ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0356

The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
Abstract Number: 1254

The Role of Regulatory T Cells (CD4+CD25+FOXP3) in Methotrexate Unresponsiveness in a Cohort of Naive Rheumatoid Arthritis Patients
Abstract Number: 0114

The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
Abstract Number: 0996

The Stimulator of Interferon Genes (STING) Protects from Bone Loss Through Regulation of Tonic and Induced Type I Interferon Pathways
Abstract Number: 0558

The Systemic Sclerosis (SSc) Risk Gene A20 (TNFAIP3) and Its Repressor DREAM Determine Susceptibility to Fibrosis
Abstract Number: 0591

The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients
Abstract Number: 1798

The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
Abstract Number: 0096

The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study
Abstract Number: 1366

The Use of Lipid-Lowering Agents in Systemic Sclerosis: Is There a Relationship with Prevalence of Digital Ulcers and Overall Survival?
Abstract Number: 1946

Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial
Abstract Number: 0738

Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Abstract Number: 0535

Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Abstract Number: 0471

Therapeutic Efficacy of BT-104, an Oral LANCL2 Agonist, for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 1147

Therapeutic Inertia and Low Patient Compliance: Major Contributors to Low Treatment Rates in Patients with Osteoporosis with Clinical Vertebral Compression Fractures
Abstract Number: 0140

Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].